Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Terminated
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of moxetumomab
pasudotox that can be given to patients with relapsed and/or refractory ALL.